Abstract: The invention is concerned with novel hypolipidemic compounds of formula (I), with processes and novel intermediates for their preparation, pharmaceutical compositions containing them and with their use in medicine, particularly in the prophylaxis and treatment of hyperlipidemic conditions, and associated diseases such as atherosclerosis.

Abstract: The invention is concerned with novel hypolipidemic compounds of formula (I), with processes and novel intermedites for their preparation, pharmaceutical compositions containing them and with their use in medicine, particularly in the prophylaxis and treatment of hyperlipidemic conditions, such as atherosclerosis.

Abstract: The present invention is concerned with processes for preparing hypolipidaemic benzothiazepine compounds of formula (I) ##STR1## wherein l is an integer of from 0 to 4; m is an integer of from 0 to 5; n is an integer of from 0 to 2; R and R' are atoms or groups independently selected from halogen, nitro, phenylalkoxy, C.sub.1-4 alkoxy, C.sub.1-6 alkyl and --O(CH.sub.2).sub.p SO.sub.3 R" wherein p is an integer of from 1 to 4 and R" is hydrogen or C.sub.1-6 alkyl, wherein said phenylalkoxy, alkoxy and alkyl groups are optionally substituted by one or more halogen atoms; R.sup.4 is C.sub.1-6 straight alkyl group; and R.sup.5 is a C.sub.2-6 straight alkyl group; and their salts, solvates and physiologically functional derivatives; and intermediates useful in said processes.

Abstract: The invention provides a compound of formula (I), wherein n is an integer of from 0 to 2; R is an optional substituent; R.sup.1 is hydrogen or C.sub.1-6 alkyl; R.sup.2 is an atom or group selected from hydrogen, C.sub.1-4 alkyl (including cycloalkyl and cycloalkylalkyl), C.sub.1-4 alkoxy, pyrryl, thienyl, pyridyl, 1,3-benzodioxolo, phenyl and naphthyl, which groups are optionally substituted; R.sup.3 is hydrogen, OH, C.sub.1-6 alkyl, C.sub.1-6 alkoxy or --O C.sub.1-6 acyl; R.sup.4 is a group independently selected from C.sub.1-6 alkyl (including cycloalkyl and cycloalkylalkyl), C.sub.2-6 alkenyl, and C.sub.2-6 -alkynyl which groups are optionally substituted; R.sup.5 is a group independently selected from C.sub.2-6 alkyl (including cycloalkyl and cycloalkylalkyl), C.sub.2-6 alkenyl and C.sub.2-6 alkynyl, which groups are optionally substituted; or R.sup.4 and R.sup.5, together with the carbon atom to which they are attached, form a C.sub.3-7 spiro cycloalkyl group which is optionally substituted; R.sup.

Abstract: The invention provides novel 1,4-benzothiazepine compounds substituted with hydroxy or a group containing hydroxy, compositions comprising such compounds and their use in the treatment or prophylaxis of treating clinical conditions in which inhibition of bile acid uptake is indicated, for example, hyperlipidemia and atherosclerosis.

Abstract: The present invention is directed to the following compounds of formula (I): ##STR1## wherein l is an integer of from 0 to 4; m is an integer of from 0 to 5; n is an integer of from 0 to 2; R and R' are atoms or groups independently selected from halogen, nitro, phenylalkoxy, C.sub.1-4 alkoxy, C.sub.1-6 alkyl and --O(CH.sub.2).sub.p SO.sub.3 R" wherein p is an integer of from 1 to 4 and R" is hydrogen or C.sub.1-6 alkyl, wherein said phenylalkoxy, alkoxy and alkyl groups are optionally substituted by one or more halogen atoms; R.sup.4 is a C.sub.1-6 straight alkyl group; and R.sup.5 is a C.sub.2-6 straight alkyl group; and their salts, solvates and physiologically functional derivatives, with processes and novel intermediates for their preparation, with pharmaceutical compositions containing them and with their use in medicine, particularly in the prophylaxis and treatment of hyperlipidaemic conditions, such as atherosclerosis.

Abstract: Compounds, pharmaceutical preparations containing same, and method of treating depression in mammals, the compounds being of the formula I ##STR1## or an acid addition salt thereof, particularly a pharmacologically or pharmaceutically acceptable salt thereof, where R and R.sup.1 are the same or different and are each hydrogen or lower alkyl, or R and R.sup.1 taken together are (CH.sub.2).sub.X where X is 4 or 5, or NRR.sup.1 is ##STR2## where Y is 3 or 4 and R.sup.3 is hydrogen or lower alkyl, or NRR.sup.1 is ##STR3## where R.sup.2 is hydrogen or lower alkyl, in the above lower alkyl has 1 to 4 carbons and may be straight or branched and n and m are the same or different and are 1, 2, or 3.

Abstract: Compounds, pharmaceutical preparations containing same, and method of treating depression in mammals, the compounds being of the formula I ##STR1## or an acid addition salt thereof, particularly a pharmacologically or pharmaceutically acceptable salt thereof, where R and R.sup.1 are the same or different and are each hydrogen or lower alkyl, or R and R.sup.1 taken together are (CH.sub.2).sub.X where X is 4 or 5, or NRR.sup.1 is ##STR2## where Y is 3 or 4 and R.sup.3 is hydrogen or lower alky, or NRR.sup.1 is ##STR3## where R.sup.2 is hydrogen or lower alkyl, in the above lower alkyl has 1 to 4 carbons and may be straight or branched and n and m are the same or different and are 1, 2, or 3.

Abstract: Compounds, pharmaceutical preparations containing same, and method of treating depression in mammals, the compounds being of the formula I ##STR1## or an acid addition salt thereof, particularly a pharmacologically or pharmaceutically acceptable salt thereof, where R and R.sup.1 are the same or different and are each hydrogen or lower alkyl, or R and R.sup.1 taken together are (CH.sub.2).sub.X where X is 4 or 5, or NRR.sup.1 is ##STR2## where Y is 3 or 4 and R.sup.3 is hydrogen or lower alkyl, or NRR.sup.1 is ##STR3## where R.sup.2 is hydrogen or lower alkyl, in the above lower alkyl has 1 to 4 carbons and may be straight or branched and n and m are the same or different and are 1, 2, or 3.

Abstract: Compounds, pharmaceutical preparations containing same, and method of treating depression in mammals, the compounds being of the formula I ##STR1## or an acid addition salt thereof, particularly a pharmacologically or pharmaceutically acceptable salt thereof, where R and R.sup.1 are the same or different and are each hydrogen or lower alkyl, or R and R.sup.1 taken together are (CH.sub.2).sub.X where X is 4 or 5, or NRR.sup.1 is ##STR2## where Y is 3 or 4 and R.sup.3 is hydrogen or lower alkyl, or NRR.sup.1 is ##STR3## where R.sup.2 is hydrogen or lower alkyl, in the above lower alkyl has 1 to 4 carbons and may be straight or branched and n and m are the same or different and are 1, 2, or 3.

Abstract: Compounds, pharmaceutical preparations containing same, and method of treating depression in mammals, the compounds being of the formula I ##STR1## or an acid addition salt thereof, particularly a pharmacologically or pharmaceutically acceptable salt thereof, where R and R.sup.1 are the same or different and are each hydrogen or lower alkyl, or R and R.sup.1 taken together are (CH.sub.2).sub.X where X is 4 or 5, or NRR.sup.1 is ##STR2## where Y is 3 or 4 and R.sup.3 is hydrogen or lower alkyl, or NRR.sup.1 is ##STR3## where R.sup.2 is hydrogen or lower alkyl, in the above lower alkyl has 1 to 4 carbons and may be straight or branched and n and m are the same or different and are 1, 2, or 3.

Abstract: Compounds, pharmaceutical preparations containing same, and method of treating depression in mammals, the compounds being of the formula I ##STR1## or an acid addition salt thereof, particularly a pharmacologically or pharmaceutically acceptable salt thereof, where R and R.sup.1 are the same or different and are each hydrogen or lower alkyl, or R and R.sup.1 taken together are (CH.sub.2).sub.X where X is 4 or 5, or NRR.sup.1 is ##STR2## where Y is 3 or 4 and R.sup.3 is hydrogen or lower alkyl, or NRR.sup.1 is ##STR3## where R.sup.2 is hydrogen or lower alkyl, in the above lower alkyl has 1 to 4 carbons and may be straight or branched and n and m are the same or different and are 1, 2, or 3.

Abstract: Compounds, pharmaceutical preparations containing same, and method of treating depression in mammals, the compounds being of the formula I ##STR1## or an acid addition salt thereof, particularly a pharmacologically or pharmaceutically acceptable salt thereof, where R and R.sup.1 are the same or different and are each hydrogen or lower alkyl, or R and R.sup.1 taken together are (CH.sub.2).sub.X where X is 4 or 5, or NRR.sup.1 is ##STR2## where Y is 3 or 4 and R.sup.3 is hydrogen or lower alkyl, or NRR.sup.1 is ##STR3## where R.sup.2 is hydrogen or lower alkyl, in the above lower alkyl has 1 to 4 carbons and may be straight or branched and n and m are the same or different and are 1, 2, or 3.